欧洲核医学协会(EANM)Focus 4 共识建议:血液系统肿瘤的分子影像与治疗
针对血液系统肿瘤核医学应用的高确定性证据匮乏与意见分歧,EANM组织专家开展三阶段共识流程,系统评价现有证据质量后,经26名专家两轮电子Delphi投票(RAND/UCLA适宜性方法)对154条声明达成139条(90%)共识,多数涉及PET在非霍奇金与霍奇金淋巴瘤中的应用。
要点
- 154条声明中139条(90%)达成共识,多数关于PET在非霍奇金和霍奇金淋巴瘤中的应用。
- 多发性骨髓瘤需更多研究确定治疗评估的最佳序列。
- 核医学医师与血液科医师期待一致文献以将体积参数、人工智能、机器学习和影像组学引入常规实践。
核心结论
- 专家小组就患者入选、影像技术、分期与反应评估、随访及治疗决策相关声明达成共识,并提供中期指导。
研究设计与样本
- 三阶段共识流程:首先系统评价现有证据质量,其次基于文献综述生成153条声明并在第一轮后追加1条,最后由26名专家对154条声明进行两轮电子Delphi评分(1分强烈不同意至9分强烈同意),采用RAND/UCLA适宜性方法分析。
- 每个主题识别出1至14篇系统评价,所有系统评价均被评为低至中等质量。
诊断标准与关键数值
- 两轮投票后,154条声明中139条(90%)达成共识。
- 多数关于PET在非霍奇金淋巴瘤和霍奇金淋巴瘤中应用的声明达成共识。
临床应用与阅片要点
- 共识可作为血液系统肿瘤分子影像与治疗决策的中期指导。
- 多发性骨髓瘤中,确定治疗评估最佳序列尚需更多研究。
局限性
- 高确定性证据匮乏。
- 每个主题的系统评价均被评为低至中等质量。
- 多发性骨髓瘤中需更多研究确定治疗评估的最佳序列。
- 核医学医师与血液科医师期待一致文献以将体积参数、人工智能、机器学习和影像组学引入常规实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Given the paucity of high-certainty evidence, and differences in opinion on the use of nuclear medicine for hematological malignancies, we embarked on a consensus process involving key experts in this area. We aimed to assess consensus within a panel of experts on issues related to patient eligibility, imaging techniques, staging and response assessment, follow-up, and treatment decision-making, and to provide interim guidance by our expert consensus. We used a three-stage consensus process. First, we systematically reviewed and appraised the quality of existing evidence. Second, we generated a list of 153 statements based on the literature review to be agreed or disagreed with, with an additional statement added after the first round. Third, the 154 statements were scored by a panel of 26 experts purposively sampled from authors of published research on haematological tumours on a 1 (strongly disagree) to 9 (strongly agree) Likert scale in a two-round electronic Delphi review. The RAND and University of California Los Angeles appropriateness method was used for analysis. Between one and 14 systematic reviews were identified on each topic. All were rated as low to moderate quality. After two rounds of voting, there was consensus on 139 (90%) of 154 of the statements. There was consensus on most statements concerning the use of PET in non-Hodgkin and Hodgkin lymphoma. In multiple myeloma, more studies are required to define the optimal sequence for treatment assessment. Furthermore, nuclear medicine physicians and haematologists are awaiting consistent literature to introduce volumetric parameters, artificial intelligence, machine learning, and radiomics into routine practice.
引用
- Nanni C, Kobe C, Baeßler B, et al. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. Lancet Haematol. 2023. PMID: 37142345. doi:10.1016/S2352-3026(23)00030-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。